Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1476
http://purl.obolibrary.org/obo/NCIT_C1476
|
|---|---|
| Preferred Name | Denileukin Diftitox |
| Definitions |
A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04) |
|---|---|
| prefLabel | Denileukin Diftitox
|
| label | Denileukin Diftitox
|
| PDQ_Closed_Trial_Search_ID | 42325
|
| code | C1476
|
| Has_Target | |
| prefixIRI | NCIT:C1476
|
| in_subset |
See more
See less
|
| Display_Name | Denileukin Diftitox
|
| Preferred_Name | Denileukin Diftitox
|
| FDA_UNII_Code | 25E79B5CTM
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Denileukin Diftitox
|
| CAS_Registry | 173146-27-5
|
| NSC Number | 714744
|
| NCI_Drug_Dictionary_ID | 42325
|
| Legacy Concept Name | Denileukin_Diftitox
|
| type | |
| ALT_DEFINITION | A drug used to treat cutaneous T-cell lymphoma that can bind the cytokine IL-2 and that has not responded to other treatment. It is also being studied in the treatment of other types of cancer. Ontak is made by combining a part of IL-2 with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and then the toxin kills the cells. Ontak is a type of immunotoxin and a type of fusion toxin.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 42325
|
| Accepted_Therapeutic_Use_For | Cutaneous T-cell lymphoma
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C0717670
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |